WEAV vs ABCL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
WEAV · Weave Communications$7.40 ▲ 0.00%
ABCL · AbCellera Biologics$11.88 ▲ 6.74%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- WEAV +15.8%
- ABCL +193.3%
Head to head
| Metric | WEAV | ABCL |
|---|---|---|
| Price | $7.40 | $11.88 |
| Change today | ▲ 0.00% | ▲ 6.74% |
| Market cap | $595.33M | $3.85B |
| Return, 3 months | +11.3% | +27.2% |
| Return, year to date | -2.5% | +247.4% |
| Return, 1 year | +6.8% | +203.8% |
| P/E (TTM) | – | – |
| P/B | 7.0 | 4.3 |
| P/E percentile vs own 5y | 11th | 7th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +15.5% | -76.3% |
| Net profit growth (YoY) | +51.1% | -59.6% |
| Gross margin | 72.4% | – |
| Operating margin | -8.7% | -318.8% |
| Net margin | -8.0% | -248.8% |
| Return on equity | -25.1% | -17.3% |
| Analyst target vs. price | 0.0% | +44.8% |
| Analyst buy share | 0% | 91% |
| RSI (14) | 63 | 48 |
| 30-day volatility | 3.3% | 85.9% |
| Max drawdown, 1 year | -42.4% | -51.8% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ABCL is the largest of the group by market value.
- ABCL has returned the most over the past year.
- WEAV is growing revenue fastest.
- WEAV keeps the most profit per dollar of sales.
- WEAV has been the calmest stock over the last 30 days.